Skip to main content

Table 1 Baseline characteristics

From: Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

  Overall (n = 675) InSTI + TDF/FTC (n = 209) RPV/FTC/TDF (n = 466) p-value
Age (years) 46.2 (39.9–51.6) 48.7 (41.8–53.3) 45.4 (39.2–50.7) 0.0002
Male gender 578(86%) 174(83%) 404(87%) 0.238
HIV risk factor     <0.0001
MSM 330(49%) 78(37%) 252(54%)  
Heterosexual 134(20%) 38(18%) 96(21%)  
IDU 88(13%) 49(23%) 39(8%)  
Other/Unknown 123(18%) 44(21%) 79(17%)  
Years since HIV diagnosis 10.3 (5.1–17.3) 13.8 (6.6–22.5) 9.1 (4.8–15.5) <0.0001
History of AIDS defining events 78(12%) 26(12%) 52(11%) 0.696
Years of ART 6.6 (3.3–14.1) 10.1 (4.0–16.8) 5.7 (3.0–11.9) <0.0001
NRTI-experience 661(98%) 206(99%) 455(98%) 0.567
NNRTI-experience 326 (48%) 88 (42%) 238 (51%) 0.037
PI-experience 533 (79%) 193 (92%) 340 (73%) <0.0001
Years with HIV-RNA <50copies/mL 3.07 (1.07–5.62) 2.96 (0.77–6.12) 3.09 (1.25–5.46) 0.493
Time spent with residual viremia (%) 47.8 (23.9–74.1) 51.7 (22.1–74.2) 46.4 (24.3–73.6) 0.437
History of failure to NRTIs 130 (19%) 70 (34%) 60 (13%) <0.0001
History of failure to NNRTIs 32 (5%) 22 (11%) 10 (2%) <0.0001
History of failure to PIs 110 (16%) 54 (26%) 56 (12%) <0.0001
Type of treatment     <0.0001
PI-based 438 (65%) 172 (82%) 266 (57%)  
NNRTI-based 205 (30%) 24 (12%) 181 (39%)  
Other 32 (5%) 13 (6%) 19 (4%)  
Nadir CD4+ count (cell/μL) 271 (160–384) 228 (122–336) 289 (205–397) <0.0001
Zenith HIV-RNA before starting ART (log 10 copies/mL) 4.85 (4.08–5.32) 4.97 (4.11–5.40) 4.80 (4.08–5.29) 0.187
CD4+ (cell/μL) 679 (517–868) 663 (451–854) 687 (542–870) 0.017
HCV-Ab+ 159 (24%) 82 (39%) 77 (17%) <0.0001
ALP (U/L) 87 (69–106) 93 (73–110) 86 (69–105) 0.040
ALT (U/L) 31 (22–47) 34 (22–63) 30 (22–43) 0.001
Total bilirubin (mg/dL) 0.57 (0.34–1.44) 0.68 (0.41–1.71) 0.50 (0.32–1.37) 0.003
FIB-4 0.89 (0.65–1.27) 1.08 (0.72–1.64) 0.84 (0.61–1.12) <0.0001
eGFR (ml/min/1.73m 2 ) 104 (93–113) 102 (90–111) 105 (95–114) 0.013
Proteinuria (mg/dL) 5 (0–10) 5 (0–10) 5 (0–10) 0.858
Total cholesterol (mg/dL) 191 (162–219) 191 (159–216) 191 (164–222) 0.168
LDL cholesterol (mg/dL) 119 (95–144) 117 (91–145) 120 (97–144) 0.407
HDL cholesterol (mg/dL) 45 (38–55) 42 (36–51) 47 (40–58) <0.0001
Total/HDL cholesterol 4.25 (3.37–5.18) 4.56 (3.43–5.23) 4.18 (3.36–5.07) 0.045
Triglycerides (mg/dL) 122 (86–180) 137 (98–215) 117 (82–166) 0.0002
Glucose (mg/dL) 85 (78–93) 87 (80–96) 84 (78–91) 0.001
Hemoglobin (10 9 /L) 15.1 (14.1–15.7) 14.9 (14.1–15.7) 15.1 (14.2–15.7) 0.315
Phosphate (mmol/L) 0.98 (0.86–1.10) 0.99 (0.85–1.13) 0.98 (0.87–10.8) 0.621
  1. ALP Alkaline phosphatase, ALT Alanine aminotransferase, ART Antiretroviral therapy, eGFR Estimated glomerular filtration rate, FIB-4 Liver fibrosis-4 index, HCV-Ab Anti-hepatitis C antibodies, HDL High density lipoprotein, IDU Intravenous drug user, InSTI Integrase strand transfer inhibitor, LDL Low density lipoprotein, MSM Man who have sex with men, NNRTI Non-nucleoside reverse transcriptase inhibitor, NRTIs Nucleoside reverse transcriptase inhibitors, PI Protease inhibitor, RPV/FTC/TDF Rilpivirine/tenofovir disoproxil fumarate/emtricitabine, TDF/FTC Tenofovir disoproxil fumarate/emtricitabine